<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727528</url>
  </required_header>
  <id_info>
    <org_study_id>D9480C00022</org_study_id>
    <nct_id>NCT04727528</nct_id>
  </id_info>
  <brief_title>Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease</brief_title>
  <acronym>NEUTRALIZE</acronym>
  <official_title>A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NEUTRALIZE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy of SZC as compared to placebo in&#xD;
      maintaining normal sK+ in patients with hyperkalemia and metabolic acidosis associated with&#xD;
      CKD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NEUTRALIZE is a prospective, randomized, double-blind, placebo-controlled, parallel,&#xD;
      multicenter, Phase IIIb study to investigate the safety and efficacy of SZC in patients with&#xD;
      hyperkalemia and low bicarbonate (metabolic acidosis ).&#xD;
&#xD;
      The study will be conducted in the United States (US) at approximately 35 investigative&#xD;
      sites.&#xD;
&#xD;
      After screening on Day 1, all eligible patients will receive open-label SZC for up to 48&#xD;
      hours. Patients who achieve normokalemia within 48 hours will be randomized 1:1 into the&#xD;
      double-blind randomized treatment phase to receive SZC or placebo. Study treatment will end&#xD;
      with the Day 29 visit, which will be followed by a follow-up visit 7 days after the last&#xD;
      administration of study medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">February 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>NEUTRALIZE is a prospective, randomized, double-blind, placebo-controlled, parallel, multicenter, Phase IIIb study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum potassium</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Occurrence (yes/no)of patients having normal sK+ between 3.5 and 5.0 mmol/L inclusive at EOT without need for rescue treatment for hyperkalemia at any point during the randomized phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum bicarbonate</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Mean change in serum bicarbonate at Day 29 compared to baseline (Day 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in serum bicarbonate of ≥3 mmol/L</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Occurrence (yes/no) of patients having an increase in serum bicarbonate of ≥3 mmol/L from baseline (Day 1) to EOT (Day 29) without need for rescue treatment for metabolic acidosis (low bicarbonate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bicarbonate ≥22 mmol/L</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Occurrence (yes/no) of patients having serum bicarbonate ≥22 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in serum bicarbonate of ≥2 mmol/L</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Occurrence (yes/no) of patients having an increase in serum bicarbonate of ≥2 mmol/L from baseline (Day 1) to EOT without need for rescue treatment for metabolic acidosis (low bicarbonate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal serum potassium between 3.5 and 5.0 mmol/L and an increase in serum bicarb of ≥3 mmol/L</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Occurrence (yes/no)of patients having normal sK+ between 3.5 and 5.0 mmol/L inclusive at EOT and an increase in serum bicarb of ≥3 mmol/L from baseline (Day 1) without need for rescue treatment for metabolic acidosis or hyperkalemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal serum potassium between 3.5 and 5.0 mmol/L and an increase in bicarb of ≥22 mmol/L</measure>
    <time_frame>Day 29</time_frame>
    <description>Occurrence (yes/no) of patients having a normal sK+ between 3.5 and 5.0 mmol/L inclusive and bicarbonate ≥22 mmol/L at Day 29 without need for rescue treatment for hyperkalemia or metabolic acidosis (low bicarbonate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for rescue medication for low sodium bicarbonate</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Occurrence (yes/no) of patients needing rescue treatment for low sodium bicarbonate any time during the randomized phase</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Spot urine ammonium</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Mean change in spot urine ammonium at Day 29 (End of Treatment) compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Spot urine citrate</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Mean change in spot urine citrate at Day 29 (End of Treatment) compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Spot urine anion gap</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Mean change in spot urine anion gap at Day 29 (End of Treatment) compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Spot urine ammonium to creatinine ratio</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Mean change in spot urine ammonium-to-creatinine ratio at Day 29 (End of Treatment) compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum aldosterone</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Mean change in serum aldosterone at Day 29 (End of Treatment) compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>From enrollment to up to 7 days post End of Treatment/Day 35</time_frame>
    <description>Percentage of subjects with treatment-emergent adverse events (TEAEs)</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From enrollment to up to 7 days post End of Treatment/Day 35</time_frame>
    <description>Percentage of subjects experiencing TEAEs by severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Withdrawal of treatment due to an adverse event</measure>
    <time_frame>From enrollment to up to 7 days post End of Treatment/Day 35</time_frame>
    <description>TEAEs leading to discontinuation of study treatment will be summarized by treatment group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperkalaemia</condition>
  <condition>Metabolic Acidosis</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Open-label correction phase (up to 48 hours)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible patients will receive SZC 10 g TID for up to 48 hours. Patients with POCT (Point-of-Care-Test) K+ ≥5.1 mmol/L after 24 hours will continue on SZC 10 g TID for another 24 hours. Patients who achieve normokalemia (defined as POCT K+ between 3.5 and 5.0 mmol/L inclusive) after receiving SZC 10 g TID for up to 48 hours will proceed to randomization.&#xD;
Patients with POCT K+ &lt;3.5mmol/L at any time during the open-label phase will be withdrawn from study treatment and will be followed per protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized, placebo controlled phase (Day 2 or 3 to Day 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to SZC 10 g QD or placebo 10 g QD. The dose of SZC/placebo will be titrated by increasing or decreasing the dose by 5 g increments at 1-week intervals to between 5 g every other day (QOD) and 15 g QD of the randomized phase to maintain normokalemia by POCT K+.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium zirconium cyclosilicate</intervention_name>
    <description>Investigational medicinal product</description>
    <arm_group_label>Open-label correction phase (up to 48 hours)</arm_group_label>
    <arm_group_label>Randomized, placebo controlled phase (Day 2 or 3 to Day 29)</arm_group_label>
    <other_name>SZC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Plabeco comparator</description>
    <arm_group_label>Open-label correction phase (up to 48 hours)</arm_group_label>
    <arm_group_label>Randomized, placebo controlled phase (Day 2 or 3 to Day 29)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged ≥18 years&#xD;
&#xD;
          -  Participants who have CKD stage 3-5, not on dialysis.&#xD;
&#xD;
          -  Two consecutive POCT K+ levels &gt;5 mmol/L to ≤5.9 mmol/L and POCT bicarbonate levels&#xD;
             between 16-20 mmol/L inclusive on 2 measurements 60 minutes apart (±15 minutes) prior&#xD;
             to the first SZC dose on study Day 1.&#xD;
&#xD;
          -  Ability to have repeated blood draws or effective venous catheterization.&#xD;
&#xD;
          -  Male and/or female. Contraceptive use by men or women should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies.&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with pseudohyperkalemia.&#xD;
&#xD;
          -  Dialysis requirement or anticipated by the investigator to require dialysis therapy&#xD;
             within 3 months, history of renal transplant, or life expectancy less than 3 months.&#xD;
&#xD;
          -  Cardiac arrhythmias requiring immediate treatment.&#xD;
&#xD;
          -  Active or suspected diabetic ketoacidosis.&#xD;
&#xD;
          -  POCT bicarbonate low enough to need emergency intervention or treatment as judged by&#xD;
             the investigator.&#xD;
&#xD;
          -  Acute/chronic worsening renal function (eg, ≥30% decline in eGFR) in the 3 months&#xD;
             before screening.&#xD;
&#xD;
          -  Current acute decompensated HF, hospitalization due to decompensated HF within 4 weeks&#xD;
             prior to screening, or myocardial infarction (MI), unstable angina, stroke or&#xD;
             transient ischemic attack (TIA) within 12 weeks prior to screening.&#xD;
&#xD;
          -  Coronary revascularization (percutaneous coronary intervention [PCI] or coronary&#xD;
             artery bypass grafting [CABG]) or valvular repair/replacement within 12 weeks prior to&#xD;
             screening or planned to undergo any of these operations.&#xD;
&#xD;
          -  Symptomatic hypotension.&#xD;
&#xD;
          -  Current exacerbation of chronic obstructive pulmonary disease (COPD)/asthma or&#xD;
             hospitalization due to exacerbation of COPD/asthma within 4 weeks of screening.&#xD;
&#xD;
          -  History of diabetic gastroparesis, bariatric surgery, bowel obstruction, swallowing&#xD;
             disorders.&#xD;
&#xD;
          -  Active malignancy requiring treatment.&#xD;
&#xD;
          -  History of QT prolongation associated with other medications that required&#xD;
             discontinuation of that medication.&#xD;
&#xD;
          -  Congenital long QT syndrome.&#xD;
&#xD;
          -  Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic&#xD;
             sustained ventricular tachycardia. Patients with atrial fibrillation controlled by&#xD;
             medication are permitted.&#xD;
&#xD;
          -  QTcF (QT interval corrected by the Fridericia method) &gt;550 msec.&#xD;
&#xD;
          -  Active treatment (within 7 days prior to screening) with SZC, sodium bicarbonate,&#xD;
             sodium polystyrene sulfonate, lactulose, or patiromer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenandoah</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

